1. Home
  2. KPTI vs EDAP Comparison

KPTI vs EDAP Comparison

Compare KPTI & EDAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$7.51

Market Cap

172.6M

Sector

Health Care

ML Signal

HOLD

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

N/A

Current Price

$4.14

Market Cap

163.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KPTI
EDAP
Founded
2008
1979
Country
United States
France
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
172.6M
163.4M
IPO Year
2013
1998

Fundamental Metrics

Financial Performance
Metric
KPTI
EDAP
Price
$7.51
$4.14
Analyst Decision
Strong Buy
Buy
Analyst Count
7
3
Target Price
$17.50
$8.50
AVG Volume (30 Days)
807.0K
54.1K
Earning Date
05-04-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$146,067,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$46.62
$7.15
P/E Ratio
N/A
N/A
Revenue Growth
0.57
N/A
52 Week Low
$3.51
$1.21
52 Week High
$10.99
$5.05

Technical Indicators

Market Signals
Indicator
KPTI
EDAP
Relative Strength Index (RSI) 40.67 46.00
Support Level $5.60 $3.64
Resistance Level $7.81 $4.24
Average True Range (ATR) 0.75 0.37
MACD -0.27 -0.06
Stochastic Oscillator 3.53 45.95

Price Performance

Historical Comparison
KPTI
EDAP

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

Share on Social Networks: